Advertisement

March 29, 2015

New Indication Allows Brilinta to Be Crushed for Patients With Difficulty Swallowing

March 30, 2015—AstraZeneca announced that the US Food and Drug Administration has approved a new administration option for acute coronary syndrome (ACS) patients who are unable to swallow the company’s Brilinta (ticagrelor) 90-mg tablets whole. A P2Y12 inhibitor, Brilinta now has US Food and Drug Adminstration approval to be crushed and administered in water by swallowing or via nasogastric tube.

The company noted that survey data show that 40% of adults in the general population experience problems swallowing pills, and this difficulty may increase with age. Moreover, some patients who experience a heart attack have difficulty swallowing medications in the emergency setting. This new administration option for Brilinta gives healthcare professionals flexibility in treating their ACS patients.

Brilinta is indicated to reduce the rate of thrombotic cardiovascular events in patients with ACS (defined as unstable angina, non-ST-elevation myocardial infarction, or ST-elevation myocardial infarction). Brilinta has been studied in ACS in combination with aspirin. Maintenance doses of aspirin > 100 mg decreased the effectiveness of Brilinta and should be avoided, advised AstraZeneca.

Advertisement


March 30, 2015

SCAI Session to Address Disruptive Technologies in Interventional Cardiology

March 30, 2015

SCAI Session to Address Disruptive Technologies in Interventional Cardiology


)